Economic Evaluation of 22 HPV Vaccination Strategies to Minimize the Risk of Penile, Anal, and Oropharyngeal Cancers in Chinese Males: A Markov Model Analysis

Modeling 22 strategies, 20 cleared China's cost-effectiveness bar; vaccinating 14-year-olds with a 4-valent vaccine won

Journal: Human Vaccines & Immunotherapeutics | Published: 2026-03-20 | Type: Journal Article | PMID: 41860356 Authors: Wang Di, Luo Weihua, Qin Ruixi, Xu Gan, Chai Peipei, Liu Bingjie, Zhou Liangru, Zhang Xin (Beijing University of Chinese Medicine; Harbin Medical University; China National Health Development Research Center) Funding/COI: Funding not listed. Authors report no conflicts of interest.

Summary

A Markov model analysis evaluated 22 HPV vaccination strategies for Chinese males — varying vaccine type (4-valent vs. 9-valent), age at vaccination (14 vs. 40), and coverage rate (10–50%) — against a no-vaccination baseline, tracking outcomes for penile, anal, and oropharyngeal cancers over a lifetime horizon. At 50% coverage, vaccinating 14-year-olds with the 9-valent vaccine averted an estimated 416,654 cancer cases and 6,229 deaths. Twenty of the 22 strategies cleared the WHO cost-effectiveness threshold of three times China's GDP per capita. The 4-valent vaccine targeting 14-year-olds emerged as the most favorable strategy on economic grounds, primarily because its lower price outweighs the modest efficacy advantage of the 9-valent formulation.

Claims

• At 50% coverage, 9-valent vaccination of 14-year-olds averted an estimated 416,654 cancer cases and 6,229 deaths over a lifetime horizon (vs. no vaccination baseline)
• 4-valent vaccination at the same coverage averted 397,205 cases and 5,939 deaths for the same cohort
• Vaccination of 40-year-olds averted more absolute cases (up to 650,764 at 50% 9-valent coverage) — but primarily because that age cohort is larger (9.785 million vs. 8.378 million), and peak cancer risk for these cancers occurs after age 45
• 20 of 22 strategies were cost-effective at the 3× GDP per capita threshold
• 4-valent vaccine cost ¥7.95 billion vs. ¥11.56 billion for 9-valent at 50% coverage for 14-year-olds; the efficacy delta (90% vs. 95%) did not offset this price gap
• Sensitivity analysis described as confirming the model's robustness

Study Quality

This is a decision-analytic Markov model, not an empirical trial. The model constructs 12 mutually exclusive health states, runs annual cycles with half-cycle correction, applies a 3% discount rate per WHO guidelines, and draws parameters from published literature and national Chinese databases. The methodology is internally coherent and consistent with how health economists typically frame vaccine cost-effectiveness. All 22 strategies are compared against no-vaccination — a reasonable counterfactual in a country where male HPV vaccination has only recently been introduced.

The main limitation inherent to this class of study is that it is only as good as its inputs. The model sources transition probabilities, cancer incidence rates, utilities, and costs from heterogeneous secondary literature, and the full parameter set is not reproduced in the abstract. Garbage-in, garbage-out applies. The model also assumes 90% and 95% vaccine efficacy without specifying the evidence base for those figures in relation to penile, anal, and oropharyngeal cancers specifically — efficacy estimates often come from female cervical cancer trials or HPV infection endpoints, not male cancer endpoints directly.

Red Flags

• No funding disclosed — the absence is noted by the authors, but for a paper with direct policy implications for vaccine purchasing, the source of institutional support matters
• Key model parameters (transition probabilities, utility values, cost inputs) are sourced from "published literature and national databases" without the full table visible in the abstract; parameter uncertainty outside the sensitivity analysis cannot be evaluated without the supplement
• Vaccine efficacy figures (90% for 4-valent, 95% for 9-valent) are presented as fixed inputs; these are likely derived from female cohort or HPV infection-clearance data, not from male cancer endpoint trials — the paper does not clarify this
• The model assumes cancer progression is strictly linear (localized → regional → distant), which is a simplification that may not reflect actual disease biology across all three cancer types equally
• 2020 epidemiological data used as the baseline; China's cancer incidence and healthcare costs will have shifted in the intervening years
• Authors are from health management/economics schools, not urology or oncology — no independent clinical validation of model structure is mentioned

Strengths

• Comprehensive coverage: 22 strategies across two age groups, two vaccine valencies, and five coverage levels in a single analysis
• Uses a recognized international cost-effectiveness threshold (3× GDP per capita per WHO guidelines) rather than an arbitrary cutoff
• Correctly identifies that the larger absolute benefit seen in 40-year-old cohorts is a population-size artifact, not a vaccine efficacy signal — this is methodologically honest
• Timely: China formally integrated HPV vaccine into its national immunization program in 2025; this paper arrives as policy windows open
• Sensitivity analysis conducted, which at minimum tests directional robustness even if details are not fully visible

Verdict

The finding that 20 of 22 male HPV vaccination strategies clear China's cost-effectiveness bar is credible in direction — similar models from the US, Netherlands, and Singapore have reached the same conclusion. The specific winner (4-valent vaccine, 14-year-old cohort) is driven largely by price, which is an honest economic argument. What this paper cannot do — and doesn't claim to do — is prove that the modeled outcomes will materialize in practice. The parameter sourcing is the critical unknown: if the efficacy and incidence inputs don't hold in the Chinese male population, the cost numbers shift accordingly. Read this as policy-oriented health economics that lends model-based support to male vaccination programs China is already starting to implement, not as a clinical effectiveness trial.